Mindfulness and mindfulness-based cognitive therapy in depression

Article written and reviewed by Dr Luca Moretti

Mindfulness refers to a set of practices involving intentional awareness of present-moment experience cultivated with a nonjudgmental attitude. In clinical settings, meditation practice should not be confused with a standardized treatment: the form with the strongest depression-specific evidence is mindfulness-based cognitive therapy (MBCT), a structured psychological program that integrates mindfulness exercises with elements of cognitive therapy. Its most established evidence base concerns relapse prevention in recurrent major depression, while more recent studies have also evaluated its use in the presence of current depressive symptoms or after an insufficient response to other psychotherapies.

MBCT is not equivalent to a meditation app, a relaxation course or a nonclinical spiritual practice. In studied protocols, it is generally delivered over approximately eight weeks, often in groups, with guided sessions, daily home practice and specifically trained instructors. The efficacy observed in trials applies to this type of structured intervention and cannot automatically be attributed to any exercise described as “mindfulness.”

Treatment structure and clinical rationale

MBCT arose from the observation that, after a depressive episode, even mild negative affective states can reactivate patterns of thinking and rumination associated with previous episodes, increasing vulnerability to relapse. Treatment teaches patients to recognize thoughts, bodily sensations and emotions early as transient mental events, reducing the tendency to react automatically or treat every negative thought as a fact. This process is often described as decentering or metacognitive awareness.

Practices may include breath awareness, body scan, sitting meditation, mindful movement and informal exercises during daily activities. Cognitive elements help identify depressive patterns and build response plans for early signs of deterioration. Treatment is not intended to “empty the mind,” suppress thoughts or produce constant calm; instead, it trains the ability to observe even unpleasant experiences without automatically turning them into ruminative chains.

Proposed mechanisms include reduced rumination, improved attentional control, greater cognitive flexibility, emotion regulation and changes in the relationship with negative self-referential thoughts. Mediation and neuroimaging studies suggest changes consistent with these processes, but no single mechanism has been demonstrated to provide an exclusive explanation of efficacy. The therapeutic relationship, group support, behavioral practice and expectations may contribute to outcomes alongside mindfulness-specific elements.

Relapse prevention in recurrent depression

Early MBCT trials showed benefit in preventing relapse or recurrence in people with recurrent depression in remission. Subsequent studies and individual-patient-data meta-analyses confirmed that, in selected populations, MBCT reduces the risk of a new episode compared with several control conditions. This effect does not mean that every patient can discontinue pharmacotherapy: decisions about maintenance antidepressant treatment should be individualized and based on relapse risk, number and severity of episodes, previous response, adverse effects and preferences.

The PREVENT trial compared MBCT with support for tapering or discontinuing maintenance antidepressants against pharmacological maintenance in people at high risk of relapse. Overall, MBCT was not superior to maintenance pharmacotherapy, but it provided a clinically reasonable alternative for some patients and helped define the role of shared decision-making. The individual-patient-data meta-analysis by Kuyken and colleagues found an advantage of MBCT over controls and a particularly interesting profile in people with greater residual symptom severity.

Relapse prevention is therefore the area in which MBCT has the most robust history of evidence. Treatment should be offered as part of a maintenance strategy rather than as a guarantee against future episodes. Risks related to the natural history of the disorder, stressful events, comorbidities, treatment interruptions and biological vulnerability remain.

Treatment of current depressive symptoms

The evidence for currently symptomatic depression is more recent and less consistent than the evidence for relapse prevention. Meta-analyses of randomized trials indicate that MBCT can reduce symptoms compared with nonspecific controls, but the number of studies, quality of comparators and follow-up duration limit certainty. Results obtained in patients in remission should not automatically be extrapolated to people with a severe acute episode.

A multicenter trial published in 2025 studied MBCT in patients with depression who had not achieved remission after high-intensity psychotherapy, showing benefit compared with treatment as usual in that specific population. This broadens the potential clinical role of MBCT as a subsequent or complementary option without making it a universal first-line treatment for every episode.

In mild or moderate depression, particularly when the patient is motivated and able to engage in practice, MBCT can be integrated with other psychotherapies, behavioral interventions and, when indicated, pharmacotherapy. In severe presentations with marked psychomotor slowing, psychosis, catatonia, high suicide risk or inability to participate in sessions, priority should be given to treatments with efficacy and speed appropriate to severity; mindfulness may be introduced later if appropriate.

Patient assessment and intervention quality

Before starting, it is advisable to define goals, illness phase, ongoing treatments, previous meditation experience and barriers to practice. Motivation is important because protocols require regular home practice; poor adherence may reduce exposure to the active elements of the program. The instructor should be able to distinguish normal difficulties in practice from clinical deterioration and coordinate with other clinicians when depression is being treated in specialist care.

Protocol fidelity matters. Session duration, instructor competence, amount of practice, cognitive component and group characteristics vary across programs; a shortened or digital intervention should not be considered equivalent to MBCT without specific data. Mobile applications may facilitate practice, but evidence for one digital product cannot automatically be transferred to another, and lack of clinical assessment reduces the ability to detect deterioration or adverse effects.

Assessment should also document residual symptoms, number of previous episodes, any relapses after medication discontinuation, level of functioning and ability to sustain attentional exercises without excessive destabilization. Quality is not simply the number of hours spent meditating: in MBCT, instructor training, the ability to integrate cognitive principles with experiential practice, supervision and management of clinical difficulties all matter. Services using shortened programs should therefore specify that these are adaptations and separately measure adherence, outcomes and safety, avoiding automatic attribution of evidence obtained with the full protocol.

Safety, adverse effects and precautions

Mindfulness is often described as inherently harmless, but meditation practices can be associated with adverse experiences. A systematic review documented psychiatric, cognitive and somatic events, with prevalence varying widely across studies and methods; anxiety, worsening mood, perceptual or cognitive changes and distress are among the reported experiences. These data do not show that standard MBCT is dangerous for most patients, but they make it inappropriate to assume that any intensive practice can be offered without screening or supervision.

Particular caution is appropriate in people with complex trauma, dissociation, psychosis, mania or hypomania, severe agitation and suicide risk. Sustained attention to internal sensations may initially increase awareness of painful emotions; the protocol should allow adaptations, grounding, reduced intensity or discontinuation when necessary. Exposure during intensive meditation retreats is very different from that of a weekly clinical program and should not be equated with MBCT.

• Persistent worsening of mood, anxiety, sleep or suicidality requires clinical reassessment, not simply “more practice.”
• The presence of psychotic or manic symptoms requires specialist assessment and changes treatment priorities.
• The program should be adapted for physical disabilities, pain, attention disorders and conditions that make prolonged postures or exercises difficult.
• Mindfulness does not replace urgent treatment of severe depressive disorders.

Role in the treatment strategy

MBCT is best regarded as a structured psychotherapy with defined indications, particularly relevant to relapse prevention in recurrent depression and with growing evidence for some symptomatic patients as well. Its value increases when it is integrated into a plan that includes illness monitoring, management of risk factors, treatment of comorbidities and a clear strategy for symptom recurrence.

Benefit does not depend on turning mindfulness into a lifestyle prescription. Some patients find it useful and sustainable, while others prefer different psychotherapeutic interventions. Choice should therefore respect preferences, accessibility, previous responses and clinical characteristics. Teaching quality and the service’s ability to recognize limitations and adverse effects are integral to appropriateness.

During follow-up, the key question is whether practice helps maintain remission, functioning and the ability to recognize early signs of relapse. In patients with recurrent depression it can be integrated with maintenance pharmacotherapy or, in selected cases and after shared decision-making, be part of a pathway involving monitored medication reduction. However, there is no rule that successful MBCT implies discontinuation of the antidepressant. The strategy should be based on the individual risk of recurrence and should specify in advance what to do if insomnia, rumination, anhedonia or other prodromal symptoms recur.

Bibliography
1. Teasdale JD et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology. 68(4), 2000: 615-623.
2. Kuyken W et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. Journal of Consulting and Clinical Psychology. 76(6), 2008: 966-978.
3. Kuyken W et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence: a randomised controlled trial. Lancet. 386(9988), 2015: 63-73.
4. Kuyken W et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry. 73(6), 2016: 565-574.
5. Williams JMG et al. Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: a randomized dismantling trial. Journal of Consulting and Clinical Psychology. 82(2), 2014: 275-286.
6. Piet J et al. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clinical Psychology Review. 31(6), 2011: 1032-1040.
7. Goldberg SB et al. Mindfulness-based cognitive therapy for the treatment of current depressive symptoms: a meta-analysis. Cognitive Behaviour Therapy. 48(6), 2019: 445-462.
8. Farias M et al. Adverse events in meditation practices and meditation-based therapies: a systematic review. Acta Psychiatrica Scandinavica. 142(5), 2020: 374-393.
9. Barnhofer T et al. Mindfulness-based cognitive therapy versus treatment as usual after non-remission to high-intensity psychological therapy for depression: a randomised controlled trial. Lancet Psychiatry. 12(6), 2025: 433-446.
10. Lam RW et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry. 69(9), 2024: 641-687.
11. Cuijpers P et al. Psychological treatment of depression: A systematic overview of a 'Meta-Analytic Research Domain'. Journal of Affective Disorders. 335, 2023: 141-151.
12. Malhi GS et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry. 55(1), 2021: 7-117.